-
As in the UFT trials, Xeloda was shown to be similar to chemotherapy that must be injected.
FORBES: How The FDA Tripped Bristol-Myers Squibb
-
In the EMILIA study, people receiving Kadcyla survived a median of 5.8 months longer compared to those taking Tykerb and Xeloda.
FORBES: A Triumph In Breast Cancer -- And Another Expensive Drug
-
At the two-year mark, 65.4% of T-DM1 patients were alive, compared to 47.5% of patients receiving Xeloda and Tykerb, researchers said.
WSJ: Roche Breast-Cancer Treatment Advances
-
Fewer people who received Kadcyla experienced Grade 3 or higher (severe) AEs than those who received Tykerb and Xeloda (43.1% vs 59.2%).
FORBES: A Triumph In Breast Cancer -- And Another Expensive Drug
-
Results were also presented on Xeloda, a similar cancer pill made by Roche (otc: RHHBY - news - people ).
FORBES: How The FDA Tripped Bristol-Myers Squibb
-
The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared to 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant.
WSJ: Roche Breast-Cancer Treatment Advances
-
The median overall survival two years after starting treatment was 23.3 months for Xeloda and Tykerb and had not been reached for patients in the T-DM1 group.
WSJ: Roche Breast-Cancer Treatment Advances
-
About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline PLC's Tykerb.
WSJ: Roche Breast-Cancer Treatment Advances
-
More patients in the Xeloda and Tykerb group had dose reductions, diarrhea, vomiting and a condition called hand-foot syndrome which is redness, swelling and pain on the hands or feet.
WSJ: Roche Breast-Cancer Treatment Advances
-
Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.
NPR: FDA Approves New Targeted Breast Cancer Drug